Biotechnology Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada – Scilex Holding (NASDAQ:SCLX) Read more
Forex Holding support in the low 1.2700 area could see the short-term trend stabilize – Scotiabank Read more
Biotechnology Scilex Holding Announces Issuance Of Halal Certification For Its ZTlido® Product By Circle H International, Inc. – Scilex Holding (NASDAQ:SCLX) Read more
Biotechnology Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche’s US Facility Acquisition For $1.2B – Roche Holding (OTC:RHHBY) Read more
Biotechnology Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered Into A Definitive Mutual Release And Settlement Agreement With Virpax Pharmaceuticals, Inc. Relating To The Previously Announced Term Sheet With Virpax In Respect Of Such Release And Settlement – Scilex Holding (NASDAQ:SCLX) Read more
Biotechnology Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt ‘Barbell Approach’ – AstraZeneca (NASDAQ:AZN), ASML Holding (NASDAQ:ASML) Read more
Biotechnology Scilex Holding Company Sets Launch Price Of $595 Per 150ml Bottle Of Gloperba®, Its First And Only Liquid Oral Version Of The Anti-Gout Medicine Colchicine Indicated For The Prophylaxis Of Painful Gout Flares In Adults; Expected Plans To Launch In The First Half Of 2024 – Scilex Holding (NASDAQ:SCLX) Read more